Evolving understanding of the renin-angiotensin-aldosterone system: Pathophysiology and targets for therapeutic intervention

American Heart Journal

Volumn 157, Issue 6 SUPPL., 2009, Pages

  Gradman, Alan H ^a,b  

^a WESTERN PENNSYLVANIA HOSPITAL   (United States)

^b TEMPLE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALISKIREN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; CANDESARTAN; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; PRORENIN; RAMIPRIL; TELMISARTAN; VALSARTAN;

ANGIONEUROTIC EDEMA; ARTERY DISEASE; BLOOD PRESSURE; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; COUGHING; DRUG EFFICACY; DRUG WITHDRAWAL; HEART FAILURE; HOMEOSTASIS; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; KIDNEY DISEASE; LOW DRUG DOSE; MONOTHERAPY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SYNCOPE;

ALDOSTERONE ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; FEMALE; HUMANS; HYPERTENSION; KIDNEY DISEASES; MALE; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RENIN-ANGIOTENSIN SYSTEM; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 65549096738     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2009.04.005     Document Type: Review

References (28)

1. Tigerstedt R., and Bergman P.G. Niere und Kreislauf. Skand Arch Physiol 8 (1898) 223-271
2. Weir M.R., and Dzau V.J. The renin-angiotensin-aldosterone system: a specific target for hypertension management. Am J Hypertens 12 12 Pt 3 (1999) 205S-213S
3. Dzau V.J. Tissue renin-angiotensin system in myocardial hypertrophy and failure. Arch Intern Med 153 (1993) 937-942
4. Siragy H.M. Angiotensin II compartmentalization within the kidney: effects of salt diet and blood pressure alterations. Curr Opin Nephrol Hypertens 15 (2006) 50-53
5. Rajagopalan S., Kurz S., Muñzel T., et al. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. J Clin Invest 97 (1996) 1916-1923
6. McConnaughey M.M., McConnaughey J.S., and Ingenito A.J. Practical considerations of the pharmacology of angiotensin receptor blockers. J Clin Pharmacol 39 (1999) 547-559
7. Kim S., and Iwao H. Molecular and cellular mechanisms of angiotensin II-mediated cardiovascular and renal diseases. Pharmacol Rev 52 1 (2000) 11-34
8. Zitnay C., and Siragy H.M. Action of angiotensin receptor subtypes on the renal tubules and vasculature: implications for volume homeostasis and atherosclerosis. Miner Electrolyte Metab 24 (1998) 362-370
9. Chrysant S.G. The pathophysiologic role of the brain renin-angiotensin system in stroke protection: clinical implications. J Clin Hypertens 9 (2007) 454-459
10. Skurk T., Lee Y.M., and Hauner H. Angiotensin II and its metabolites stimulate PAI-1 protein release from human adipocytes in primary culture. Hypertension 37 (2001) 1336-1340
11. Gesualdo L., Ranieri E., Monno R., et al. Angiotensin IV stimulates plasminogen activator inhibitor-1 expression in proximal tubular epithelial cells. Kidney Int 56 (1999) 461-470
12. Jacoby D.S., and Rader D.J. Renin-angiotensin system and atherothrombotic disease: from genes to treatment. Arch Intern Med 163 (2003) 1155-1164
13. Nguyen G., Delarue F., Burckle C., et al. Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. J Clin Invest 109 (2002) 1417-1427
14. Suzuki F., Hayakawa M., Nakagawa T., et al. Human prorenin has "gate and handle" regions for its non-proteolytic activation. J Biol Chem 278 (2003) 22217-22222
15. Methot D., Siversides D.W., and Reudelhuber T.L. In vivo enzymatic assay reveals catalytic activity of the human renin precursor in tissues. Circ Res 84 (1999) 1067-1072
16. Ichihara A., Hayashi M., Kaneshiro Y., et al. Inhibition of diabetic nephropathy by a decoy peptide corresponding to the "handle" region for nonproteolytic activation of prorenin. J Clin Invest 114 (2004) 1128-1135
17. Ichihara A., Suzuki F., Nakagawa T., et al. Prorenin receptor blockade inhibits development of glomerulosclerosis in diabetic angiotensin II type 1a receptor-deficient mice. J Am Soc Nephrol 17 (2006) 1950-1961
18. Ichihara A., Kaneshiro Y., Takemitsu T., et al. Nonproteolytic activation of prorenin contributes to development of cardiac fibrosis in genetic hypertension. Hypertension 47 (2006) 894-900
19. Ichihara A., Kaneshiro Y., and Suzuki F. Prorenin receptor blockers: effects on cardiovascular complications of diabetes and hypertension. Expert Opin Investig Drugs 15 (2006) 1137-1139
20. Biollaz J., Brunner H.R., Gavras I., et al. Antihypertensive therapy with MK 421: angiotensin II-renin relationships to evaluate efficacy of converting enzyme blockade. J Cardiovasc Pharmacol 4 (1982) 966-972
21. Azizi M., Menard J., Bissery A., et al. Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II-renin feedback interruption. J Am Soc Nephrol 15 (2004) 3126-3133
22. Stanton A., Jensen C., Nussberger J., et al. Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren. Hypertension 42 (2003) 1137-1143
23. Teo K., Yusuf S., Sleight P., et al. Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials. Am Heart J 148 (2004) 52-61
24. Yusuf S. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med (2008) [Electronic publication ahead of print]
25. Pfeffer M.A., McMurray J.J., Velazquez E.J., et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 349 (2003) 1893-1906
26. McMurray J.J., Ostergren J., Swedberg K., et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting enzyme inhibitors: the CHARM-Added trial. Lancet 362 (2003) 767-771
27. Kunz R., Wolbers M., Glass T., et al. The COOPERATE trial: a letter of concern. Lancet 371 (2008) 1575-1576
28. Phillips C.O., Kashani A., Ko D.K., et al. Adverse effects of combination angiotensin II receptor blockers plus angiotensin-converting enzyme inhibitors for left ventricular dysfunction: a quantitative review of data from randomized clinical trials. Arch Intern Med 167 (2007) 1930-1936